Ginkgolide B

Drug Profile

Ginkgolide B

Alternative Names: BN 52021

Latest Information Update: 21 Aug 2009

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Ipsen
  • Developer Ipsen; Nonindustrial sources
  • Class Lactones; Small molecules
  • Mechanism of Action Immunosuppressants; Platelet activating factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Arrhythmias; Arterial thrombosis; Asthma; Cancer; Gram-negative infections; Ischaemic heart disorders; Lung transplant rejection; Multiple sclerosis; Peptic ulcer; Renal transplant rejection; Septic shock; Xenotransplant rejection

Most Recent Events

  • 17 Nov 2002 Discontinued - Preclinical for Cancer in France (unspecified route)
  • 17 Nov 2002 Discontinued for Cancer in Hungary (unspecified route)
  • 14 Nov 2002 Discontinued - phase III for Septic shock in Europe (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top